Back to search results

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

This study is creating a collection of samples and information from people with hereditary cancers (cancers that can run in families) or solid tumors with certain genetic changes. The goal is to better understand these cancers and develop new treatments. Researchers will collect blood, tissue, and excess fluid samples during your routine medical procedures, not as extra study procedures. They will also review your medical records. The study aims to develop models of these cancers from the collected samples, which will help researchers study how they grow and respond to treatments. This study is for adults aged 18 and older.

Study design
This is an observational study, meaning participants are not given a specific treatment. It plans to enroll up to 50,000 participants.
What's involved
If you join, samples of your blood, tissue, or excess fluid will be collected during routine medical procedures you would have anyway. Your medical chart will also be reviewed.
Compensation
Not stated in the trial record.
Follow-up
The primary goal of developing tumor models will be measured for up to 10 years.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06895681

UCSF Biobank for Hereditary Cancers and Tumor-Associated Mutations

Withdrawn
Not specifiedAges 18+Observational
University of California, San Francisco
Updated 2026-09-02 on ClinicalTrials.gov
What's tested:Blood SampleTissue SampleExcess fluid SampleMedical Chart Review

At a glance

Recruiting sites

Site status isn't published for this study.

What they're measuring
Develop participant-derived tumor models of hereditary cancers
Measured over Up to 10 years

Conditions

Solid Tumor
Solid Tumor, Adult
Somatic Mutation
Solid Tumor, Unspecified, Adult
Hereditary Cancer

Explore related trials

Hereditary Malignant NeoplasmSolid Neoplasm

Study leadership

  • Varun Monga, MBBS · PRINCIPAL_INVESTIGATOR · University of California, San Francisco

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Develop participant-derived tumor models of hereditary cancersUp to 10 years

    Participant-derived models may include (but are not limited to) xenografts (PDX), organoids (PDO), and cell lines (PDCLs). These models recapitulate the biology and tissue context of the original tumors from which they are derived and can be used to study effective therapeutic strategies.